Unity Biotechnology, Inc. (0YC0.L)
USD 1.03
(0.39%)
USD 1.03
(0.39%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 44.66 Million USD | -56.81% |
| 2022 | 57.8 Million USD | -5.93% |
| 2021 | 61.44 Million USD | -32.72% |
| 2020 | 91.33 Million USD | 0.36% |
| 2019 | 91 Million USD | 21.46% |
| 2018 | 74.92 Million USD | 59.44% |
| 2017 | 46.99 Million USD | 149.36% |
| 2016 | 18.84 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 7.87 Million USD | 2.96% |
| 2024 Q2 | 9.95 Million USD | 26.5% |
| 2024 Q3 | 6.6 Million USD | -33.7% |
| 2023 Q2 | 11.96 Million USD | 12.29% |
| 2023 Q4 | 7.64 Million USD | -48.79% |
| 2023 FY | 38.98 Million USD | -32.56% |
| 2023 Q1 | 10.65 Million USD | -23.45% |
| 2023 Q3 | 14.93 Million USD | 24.82% |
| 2022 Q4 | 13.91 Million USD | 5.99% |
| 2022 Q3 | 13.13 Million USD | 5.09% |
| 2022 FY | 57.8 Million USD | -5.93% |
| 2022 Q2 | 12.49 Million USD | -31.6% |
| 2022 Q1 | 18.26 Million USD | 24.42% |
| 2021 Q1 | 14.94 Million USD | -18.4% |
| 2021 FY | 61.44 Million USD | -32.72% |
| 2021 Q4 | 14.68 Million USD | -0.98% |
| 2021 Q3 | 14.82 Million USD | -12.76% |
| 2021 Q2 | 16.99 Million USD | 13.74% |
| 2020 Q1 | 25.21 Million USD | 9.1% |
| 2020 FY | 91.33 Million USD | 0.36% |
| 2020 Q4 | 18.31 Million USD | -27.79% |
| 2020 Q2 | 22.44 Million USD | -11.0% |
| 2020 Q3 | 25.36 Million USD | 13.0% |
| 2019 Q3 | 23.46 Million USD | 0.13% |
| 2019 Q1 | 20.98 Million USD | 1.56% |
| 2019 FY | 91 Million USD | 21.46% |
| 2019 Q4 | 23.11 Million USD | -1.51% |
| 2019 Q2 | 23.43 Million USD | 11.71% |
| 2018 Q2 | 19.04 Million USD | 15.52% |
| 2018 FY | 74.92 Million USD | 59.44% |
| 2018 Q1 | 16.48 Million USD | 16.33% |
| 2018 Q4 | 20.65 Million USD | 10.23% |
| 2018 Q3 | 18.74 Million USD | -1.57% |
| 2017 Q2 | 11.69 Million USD | 29.4% |
| 2017 FY | 46.99 Million USD | 149.36% |
| 2017 Q1 | 9.04 Million USD | 0.0% |
| 2017 Q4 | 14.16 Million USD | 17.26% |
| 2017 Q3 | 12.08 Million USD | 3.29% |
| 2016 FY | 18.84 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Editas Medicine, Inc. | 247.3 Million USD | 81.938% |
| Dynavax Technologies Corporation | 219.14 Million USD | 79.618% |
| Cara Therapeutics, Inc. | 142.46 Million USD | 68.647% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 99.89% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 91.557% |
| Perrigo Company plc | 1.52 Billion USD | 97.078% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 83.798% |
| Illumina, Inc. | 3.81 Billion USD | 98.829% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 99.564% |
| Nektar Therapeutics | 190.9 Million USD | 76.602% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 90.096% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 97.824% |
| Heron Therapeutics, Inc. | 120.65 Million USD | 62.98% |
| Waters Corporation | 943.51 Million USD | 95.266% |
| Biogen Inc. | 5.2 Billion USD | 99.142% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 80.467% |
| Evolus, Inc. | 189.75 Million USD | 76.461% |
| Adicet Bio, Inc. | 152.03 Million USD | 70.621% |
| bluebird bio, Inc. | 240.23 Million USD | 81.407% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -267.902% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 83.572% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 96.718% |
| FibroGen, Inc. | 398.11 Million USD | 88.78% |
| Homology Medicines, Inc. | 9.87 Million USD | -352.324% |
| Geron Corporation | 70.44 Million USD | 36.589% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 97.519% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 89.555% |
| Myriad Genetics, Inc. | 600.1 Million USD | 92.557% |
| Viking Therapeutics, Inc. | 100.82 Million USD | 55.699% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 91.902% |
| Zoetis Inc. | 2.76 Billion USD | 98.385% |
| Abeona Therapeutics Inc. | 48.5 Million USD | 7.907% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 95.9% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 99.065% |
| uniQure N.V. | 285.08 Million USD | 84.332% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -14.083% |
| Verastem, Inc. | 92.08 Million USD | 51.493% |
| Imunon, Inc. | 21.03 Million USD | -112.392% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -221.123% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 97.442% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 98.413% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 97.888% |
| OPKO Health, Inc. | 574.68 Million USD | 92.228% |
| Exelixis, Inc. | 1.58 Billion USD | 97.185% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 97.202% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 87.882% |
| Anavex Life Sciences Corp. | 55.75 Million USD | 19.888% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 90.623% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 94.27% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 85.077% |
| Blueprint Medicines Corporation | 722.86 Million USD | 93.821% |
| Insmed Incorporated | 949.26 Million USD | 95.295% |
| TG Therapeutics, Inc. | 198.47 Million USD | 77.495% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 89.074% |
| Incyte Corporation | 1.19 Billion USD | 96.248% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 95.722% |